Metfomin
ApprovedSmall molecule
Metfomin is one of 164 small molecule programs targeting Cognitive impairment. It is currently in Approved.
5
Indications
5
Total Trials
2
Active Trials
163
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Metfomin
UUniversity of Texas Southwestern Medical Center
Approved
Adriamycin
GGynecologic Oncology Group
Preclinical
Nolvadex
SSan Diego Pacific Oncology & Hematology Associates
Preclinical
Prolia
AmgenPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
QS21
MMemorial Sloan Kettering Cancer Center
Preclinical
Neoadjuvant Therapy
SSun Yat-sen University
Preclinical
Vit D
PPost Graduate Institute of Medical Education and Research, Chandigarh
Preclinical
Recombinant Human Endostatin
PPeking University Third Hospital
Preclinical
Lipegfilgrastim
Merck & Co.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Polycystic Ovary Syndrome1 trial
The Combined Effect of N-Acetyl Cysteine and Metformin in Polycystic Ovary Syndrome Patients
Recruiting·—·Phase 3·NCT06836128·102 enrolled
Breast Cancer1 trial
Obesity1 trial
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity
Completed·—·Phase 4·NCT07120828·260 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Metfomin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details